Skip to Content

33,005 Results Found

  • Review
  • Open Access
25 Citations
6,992 Views
11 Pages

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond

  • Dario Roccatello,
  • Roberta Fenoglio,
  • Savino Sciascia,
  • Carla Naretto,
  • Daniela Rossi,
  • Michela Ferro,
  • Antonella Barreca,
  • Fabio Malavasi and
  • Simone Baldovino

Immunoglobulin light chain amyloidosis (AL amyloidosis) is a rare systemic disease characterized by monoclonal light chains (LCs) depositing in tissue as insoluble fibrils, causing irreversible tissue damage. The mechanisms involved in aggregation an...

  • Article
  • Open Access
13 Citations
7,220 Views
13 Pages

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model

  • Beatrice Anna Zannetti,
  • Angelo Corso Faini,
  • Evita Massari,
  • Massimo Geuna,
  • Enrico Maffini,
  • Giovanni Poletti,
  • Claudio Cerchione,
  • Giovanni Martinelli,
  • Fabio Malavasi and
  • Francesco Lanza

11 December 2020

Multiple myeloma (MM) is a hematological disease characterized by the proliferation and accumulation of malignant plasmacells (PCs) in the bone marrow (BM). Despite widespread use of high-dose chemotherapy in combination with autologous stem cell tra...

  • Review
  • Open Access
121 Citations
14,949 Views
10 Pages

CD38 in Neurodegeneration and Neuroinflammation

  • Serge Guerreiro,
  • Anne-Laure Privat,
  • Laurence Bressac and
  • Damien Toulorge

18 February 2020

Neurodegenerative diseases are characterized by neuronal degeneration as well as neuroinflammation. While CD38 is strongly expressed in brain cells including neurons, astrocytes as well as microglial cells, the role played by CD38 in neurodegeneratio...

  • Review
  • Open Access
47 Citations
9,617 Views
16 Pages

CD38, CD157, and RAGE as Molecular Determinants for Social Behavior

  • Haruhiro Higashida,
  • Minako Hashii,
  • Yukie Tanaka,
  • Shigeru Matsukawa,
  • Yoshihiro Higuchi,
  • Ryosuke Gabata,
  • Makoto Tsubomoto,
  • Noriko Seishima,
  • Mitsuyo Teramachi and
  • Olga Lopatina
  • + 13 authors

25 December 2019

Recent studies provide evidence to support that cluster of differentiation 38 (CD38) and CD157 meaningfully act in the brain as neuroregulators. They primarily affect social behaviors. Social behaviors are impaired in Cd38 and Cd157 knockout mice. Si...

  • Review
  • Open Access
117 Citations
17,334 Views
15 Pages

Roles of CD38 in the Immune Response to Infection

  • Estibaliz Glaría and
  • Annabel F. Valledor

16 January 2020

CD38 is a multifunctional protein widely expressed in cells from the immune system and as a soluble form in biological fluids. CD38 expression is up-regulated by an array of inflammatory mediators, and it is frequently used as a cell activation marke...

  • Review
  • Open Access
3 Citations
5,590 Views
17 Pages

The CD39/CD73/Adenosine and NAD/CD38/CD203a/CD73 Axis in Cutaneous T-Cell Lymphomas

  • Liyun Lin,
  • Gabriele Roccuzzo,
  • Yuliya Yakymiv,
  • Sara Marchisio,
  • Erika Ortolan,
  • Ada Funaro,
  • Rebecca Senetta,
  • Valentina Pala,
  • Martine Bagot and
  • Pietro Quaglino
  • + 4 authors

19 February 2025

Cutaneous T-cell lymphoma (CTCL), characterized by malignant T-cell proliferation primarily in the skin, includes subtypes such as mycosis fungoides (MF) and Sézary syndrome (SS). The tumor microenvironment (TME) is central to their pathogenes...

  • Review
  • Open Access
40 Citations
7,513 Views
18 Pages

The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy

  • Yu Jun Wo,
  • Adelia Shin Ping Gan,
  • Xinru Lim,
  • Isabel Shu Ying Tay,
  • Sherlly Lim,
  • Jeffrey Chun Tatt Lim and
  • Joe Poh Sheng Yeong

20 December 2019

The tumor microenvironment (TME) consists of extracellular matrix proteins, immune cells, vascular cells, lymphatics and fibroblasts. Under normal physiological conditions, tissue homeostasis protects against tumor development. However, under patholo...

  • Viewpoint
  • Open Access
17 Citations
5,043 Views
5 Pages

6 February 2020

During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line tre...

  • Review
  • Open Access
28 Citations
9,754 Views
28 Pages

Targeting CD38 in Neoplasms and Non-Cancer Diseases

  • Wojciech Szlasa,
  • Jakub Czarny,
  • Natalia Sauer,
  • Katarzyna Rakoczy,
  • Natalia Szymańska,
  • Jakub Stecko,
  • Maksymilian Kołodziej,
  • Maciej Kaźmierczak and
  • Ewa Barg

28 August 2022

CD38 is a myeloid antigen present both on the cell membrane and in the intracellular compartment of the cell. Its occurrence is often enhanced in cancer cells, thus making it a potential target in anticancer therapy. Daratumumab and isatuximab alread...

  • Review
  • Open Access
135 Citations
15,904 Views
26 Pages

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

  • Thomas G. Martin,
  • Kathryn Corzo,
  • Marielle Chiron,
  • Helgi van de Velde,
  • Giovanni Abbadessa,
  • Frank Campana,
  • Malini Solanki,
  • Robin Meng,
  • Helen Lee and
  • Kenneth C. Anderson
  • + 3 authors

26 November 2019

CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at re...

  • Article
  • Open Access
30 Citations
4,811 Views
19 Pages

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

  • Christie P. M. Verkleij,
  • Amy Jhatakia,
  • Marloes E. C. Broekmans,
  • Kristine A. Frerichs,
  • Sonja Zweegman,
  • Tuna Mutis,
  • Natalie A. Bezman and
  • Niels W. C. J. van de Donk

10 December 2020

The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its effects on T-cell immunity through depletion of CD38+ regulatory T-cells, regulatory B-cells, and...

  • Review
  • Open Access
72 Citations
15,813 Views
21 Pages

CD38: T Cell Immuno-Metabolic Modulator

  • Anwesha Kar,
  • Shikhar Mehrotra and
  • Shilpak Chatterjee

17 July 2020

Activation and subsequent differentiation of T cells following antigenic stimulation are triggered by highly coordinated signaling events that lead to instilling cells with a discrete metabolic and transcriptional feature. Compelling studies indicate...

  • Article
  • Open Access
16 Citations
6,403 Views
14 Pages

The Role of CD38 on the Function of Regulatory B Cells in a Murine Model of Lupus

  • Brianna Burlock,
  • Gabrielle Richardson,
  • Sonia García-Rodríguez,
  • Salvador Guerrero,
  • Mercedes Zubiaur and
  • Jaime Sancho

25 September 2018

Previous work from our group has shown that Cd38−/− mice develop a milder pristane-induced lupus disease than WT or Art2−/− counterparts, demonstrating a new role for CD38 in promoting aberrant inflammation and lupus-like auto...

  • Article
  • Open Access
5 Citations
3,829 Views
15 Pages

Expression of CD38 in Mast Cells: Cytological and Histotopographic Features

  • Dmitri Atiakshin,
  • Vera Samoilova,
  • Igor Buchwalow and
  • Markus Tiemann

22 September 2021

The biological significance of the CD38 molecule goes beyond metabolic, enzymatic, and proliferative functions. CD38 possesses the functions of an exoenzyme and receptor, and is actively involved in the mechanisms of adhesion, migration, intercellula...

  • Article
  • Open Access
2 Citations
2,136 Views
13 Pages

Evaluation of Regulatory B Cell Subpopulations CD24++CD38++, CD24++CD27+, Plasmablasts and Their Correlation with T Regs CD3+CD4+CD25+FOXP3+ in Dialysis Patients and Early Post-Transplant Rejection-Free Kidney Recipients

  • Ariadni Fouza,
  • Asimina Fylaktou,
  • Anneta Tagkouta,
  • Maria Daoudaki,
  • Lampros Vagiotas,
  • Efstratios Kasimatis,
  • Maria Stangou,
  • Aliki Xochelli,
  • Vasiliki Nikolaidou and
  • Nikolaos Antoniadis
  • + 4 authors

24 May 2024

Background: B and T regulatory cells, also known as Bregs and Tregs, are involved in kidney transplantation. The purpose of this study is to monitor changes in the frequency and absolute numbers of Tregs (CD3+CD4+CD25+FoxP3+), transitional Bregs (tBr...

  • Article
  • Open Access
10 Citations
4,867 Views
21 Pages

Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells

  • Avishay Edri,
  • Nimrod Ben-Haim,
  • Astar Hailu,
  • Nurit Brycman,
  • Orit Berhani-Zipori,
  • Julia Rifman,
  • Sherri Cohen,
  • Dima Yackoubov,
  • Michael Rosenberg and
  • Yona Geffen
  • + 6 authors

7 December 2023

Natural killer (NK) cells are a vital component of cancer immune surveillance. They provide a rapid and potent immune response, including direct cytotoxicity and mobilization of the immune system, without the need for antigen processing and presentat...

  • Article
  • Open Access
1,172 Views
17 Pages

Pathological Mechanisms in Sjögren’s Disease Likely Involve the ADP-Ribosyl Cyclase Family Members: CD38 and CD157

  • Michaela Rosecka,
  • Martina Kolackova,
  • Moeina Afshari,
  • Eva Jozifkova,
  • Radovan Slezak,
  • Jan Krejsek and
  • Vladimira Radochova

28 November 2025

Peripheral blood serves both as a source of effector immune cells that migrate to exocrine glands and as a reflection of the immunological changes occurring in patients with Sjögren’s disease (SjD). These changes may be linked to the clini...

  • Article
  • Open Access
12 Citations
4,972 Views
13 Pages

CD38 Correlates with an Immunosuppressive Treg Phenotype in Lupus-Prone Mice

  • Jocelyn C. Pérez-Lara,
  • Enrique Espinosa,
  • Leopoldo Santos-Argumedo,
  • Héctor Romero-Ramírez,
  • Gabriela López-Herrera,
  • Fabio García-García,
  • Claudia Sandoval-Montes,
  • Vianney Ortiz-Navarrete,
  • Mónica Flores-Muñoz and
  • Juan C. Rodríguez-Alba

5 November 2021

CD38 is a transmembrane glycoprotein expressed by T-cells. It has been reported that patients with systemic lupus erythematosus (SLE) showed increased CD38+CD25+ T-cells correlating with immune activation and clinical signs. Contrariwise, CD38 defici...

  • Article
  • Open Access
5 Citations
3,442 Views
21 Pages

T Cells Immunophenotyping and CD38 Overexpression as Hallmarks of the Severity of COVID-19 and Predictors of Patients’ Outcomes

  • Nesrin I. Tarbiah,
  • Nuha A. Alkhattabi,
  • Abdullah J. Alsahafi,
  • Hani S. Aljahdali,
  • Husam M. Joharjy,
  • Maryam H. Al-Zahrani,
  • Aliaa M. Sabban,
  • Rana A. Alghamdi,
  • Maha J. Balgoon and
  • Reham A. Khalifa

16 January 2023

Background: By the end of 2019, the COVID-19 pandemic spread all around the world with a wide spectrum of clinical presentations ranging from mild to moderate to severe or critical cases. T cell subtype dysregulation is mostly involved in the immunop...

  • Review
  • Open Access
21 Citations
6,089 Views
18 Pages

Calcium (Ca2+) is a ubiquitous and fundamental signaling component that is utilized by cells to regulate a diverse range of cellular functions, such as insulin secretion from pancreatic β-cells of the islets of Langerhans. Cyclic ADP-ribose (cADPR),...

  • Review
  • Open Access
36 Citations
6,213 Views
9 Pages

The Anti-CD38 Antibody Therapy in Multiple Myeloma

  • Maria Teresa Petrucci and
  • Federico Vozella

12 December 2019

Multiple myeloma (MM) is the second-most common hematologic malignancy after diffuse large B-cell lymphoma. Despite the improvement in response and survival rates following the introduction of novel therapies, only a few patients are cured, and the m...

  • Article
  • Open Access
28 Citations
7,589 Views
19 Pages

Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE

  • Marie Burns,
  • Lennard Ostendorf,
  • Robert Biesen,
  • Andreas Grützkau,
  • Falk Hiepe,
  • Henrik E. Mei and
  • Tobias Alexander

28 February 2021

Given its uniformly high expression on plasma cells, CD38 has been considered as a therapeutic target in patients with systemic lupus erythematosus (SLE). Herein, we investigate the distribution of CD38 expression by peripheral blood leukocyte lineag...

  • Article
  • Open Access
15 Citations
5,633 Views
22 Pages

Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells

  • M. Tommy Gambles,
  • Jiahui Li,
  • Jiawei Wang,
  • Douglas Sborov,
  • Jiyuan Yang and
  • Jindřich Kopeček

31 July 2021

Recently, we designed an inventive paradigm in nanomedicine—drug-free macromolecular therapeutics (DFMT). The ability of DFMT to induce apoptosis is based on biorecognition at cell surface, and crosslinking of receptors without the participation of l...

  • Review
  • Open Access
25 Citations
6,830 Views
24 Pages

IFN-γ and CD38 in Hyperprogressive Cancer Development

  • Stefania Angelicola,
  • Francesca Ruzzi,
  • Lorena Landuzzi,
  • Laura Scalambra,
  • Francesco Gelsomino,
  • Andrea Ardizzoni,
  • Patrizia Nanni,
  • Pier-Luigi Lollini and
  • Arianna Palladini

15 January 2021

Immune checkpoint inhibitors (ICIs) improve the survival of patients with multiple types of cancer. However, low response rates and atypical responses limit their success in clinical applications. The paradoxical acceleration of tumor growth after tr...

  • Article
  • Open Access
17 Citations
4,079 Views
15 Pages

CD38 Deficiency Alleviates Diabetic Cardiomyopathy by Coordinately Inhibiting Pyroptosis and Apoptosis

  • Ling-Fang Wang,
  • Qian Li,
  • Ke Wen,
  • Qi-Hang Zhao,
  • Ya-Ting Zhang,
  • Jia-Le Zhao,
  • Qi Ding,
  • Xiao-Hui Guan,
  • Yun-Fei Xiao and
  • Hong-Bo Xin
  • + 1 author

6 November 2023

Diabetic cardiomyopathy is one of the diabetes mellitus-induced cardiovascular complications that can result in heart failure in severe cases, which is characterized by cardiomyocyte apoptosis, local inflammation, oxidative stress, and myocardial fib...

  • Viewpoint
  • Open Access
28 Citations
5,790 Views
9 Pages

27 December 2019

CD38 is a type II glycoprotein highly expressed on plasmablasts, short-lived and long-lived plasma cells, but weakly expressed on other lymphoid cells, myeloid cells and non-hematopoietic cells. This expression pattern makes CD38 an interesting targe...

  • Review
  • Open Access
6 Citations
4,410 Views
11 Pages

Role of CD38 in Adipose Tissue: Tuning Coenzyme Availability?

  • Andrea Benzi,
  • Alessia Grozio,
  • Sonia Spinelli,
  • Laura Sturla,
  • Andreas H. Guse,
  • Antonio De Flora,
  • Elena Zocchi,
  • Joerg Heeren and
  • Santina Bruzzone

23 October 2021

Nicotinamide adenine dinucleotide (NAD+) is a fundamental molecule in the regulation of energy metabolism, representing both a coenzyme and a substrate for different NAD+ degrading enzymes. Among these enzymes, CD38 can be seen under two perspectives...

  • Review
  • Open Access
46 Citations
10,422 Views
20 Pages

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

  • Laurens E. Franssen,
  • Claudia A. M. Stege,
  • Sonja Zweegman,
  • Niels W. C. J. van de Donk and
  • Inger S. Nijhof

22 April 2020

Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple myeloma (MM). CD38−directed antibodies have several mechanisms of action. Fc−dependent immune effector mechanisms include complement-dependent cytotoxicity...

  • Review
  • Open Access
41 Citations
9,335 Views
12 Pages

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias

  • Renato Zambello,
  • Gregorio Barilà,
  • Sabrina Manni,
  • Francesco Piazza and
  • Gianpietro Semenzato

21 March 2020

Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a cl...

  • Article
  • Open Access
14 Citations
5,251 Views
19 Pages

25 October 2022

Daratumumab (DARA) has improved the outcome of treatment of multiple myeloma (MM). DARA acts via complement-dependent and -independent mechanisms. Resistance to DARA may result from upregulation of the complement inhibitory proteins CD55 and CD59, do...

  • Review
  • Open Access
34 Citations
6,459 Views
16 Pages

The Circular Life of Human CD38: From Basic Science to Clinics and Back

  • Alberto L. Horenstein,
  • Angelo C. Faini,
  • Fabio Morandi,
  • Cristiano Bracci,
  • Francesco Lanza,
  • Nicola Giuliani,
  • Aneel Paulus and
  • Fabio Malavasi

21 October 2020

Monoclonal antibodies (mAbs) were initially considered as a possible “magic bullet” for in vivo elimination of tumor cells. mAbs represented the first step: however, as they were murine in nature (the earliest experience on the field), th...

  • Article
  • Open Access
5 Citations
3,634 Views
19 Pages

Role of Liver CD38 in the Regulation of Metabolic Pathways during Cold-Induced Thermogenesis in Mice

  • Andrea Benzi,
  • Sonia Spinelli,
  • Laura Sturla,
  • Markus Heine,
  • Alexander W. Fischer,
  • Friedrich Koch-Nolte,
  • Hans-Willi Mittrücker,
  • Andreas H. Guse,
  • Antonio De Flora and
  • Santina Bruzzone
  • + 1 author

28 November 2022

Boosting NAD+ levels are considered a promising means to promote healthy aging and ameliorate dysfunctional metabolism. The expression of CD38, the major NAD+-consuming enzyme, is downregulated during thermogenesis in both brown and white adipose tis...

  • Article
  • Open Access
4 Citations
3,179 Views
12 Pages

CD38 Enhances TLR9 Expression and Activates NLRP3 Inflammasome after Porcine Parvovirus Infection

  • Yi Zheng,
  • Yixuan Xu,
  • Weimin Xu,
  • Sanjie Cao,
  • Qigui Yan,
  • Xiaobo Huang,
  • Yiping Wen,
  • Qin Zhao,
  • Senyan Du and
  • Rui Wu
  • + 2 authors

25 May 2022

(1) Background: Porcine Parvovirus (PPV) is a single-stranded DNA virus without envelope which causes great harm in relation to porcine reproductive disorders in clinic. Cluster of Differentiation 38 (CD38) is a transmembrane protein widely existing...

  • Article
  • Open Access
6 Citations
2,564 Views
15 Pages

A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma

  • Pierre V. Candelaria,
  • Miguel Nava,
  • Tracy R. Daniels-Wells and
  • Manuel L. Penichet

13 September 2023

Multiple myeloma (MM) is an incurable malignancy of plasma cells and the second most common hematologic malignancy in the United States. Although antibodies in clinical cancer therapy are generally of the IgG class, antibodies of the IgE class have a...

  • Article
  • Open Access
3 Citations
3,295 Views
20 Pages

CD38 Inhibitor 78c Attenuates Pro-Inflammatory Cytokine Expression and Osteoclastogenesis in Macrophages

  • William Lory,
  • Nityananda Chowdhury,
  • Bridgette Wellslager,
  • Subramanya Pandruvada,
  • Yan Huang,
  • Özlem Yilmaz and
  • Hong Yu

28 November 2024

CD38, a nicotinamide adenine dinucleotide (NAD+) glycohydrolase, increases during infection or inflammation. Therefore, we aimed to evaluate the effects of a CD38 inhibitor (78c) on NAD+ levels, IL-1β, IL-6, TNF-α cytokine expressions, and...

  • Review
  • Open Access
32 Citations
10,683 Views
16 Pages

26 March 2020

The CD38 antigen is expressed in several hematological malignancies, and the anti-CD38 monoclonal antibodies Daratumumab and Isatuximab have an established role in the therapy of multiple myeloma. However, data on the therapeutic utility of CD38 targ...

  • Review
  • Open Access
9 Citations
6,852 Views
22 Pages

12 February 2023

Aging is a major risk factor for the leading causes of mortality, and the incidence of age-related diseases including cardiovascular disease, kidney disease and metabolic disease increases with age. NAD+ is a classic coenzyme that exists in all speci...

  • Brief Report
  • Open Access
3 Citations
3,472 Views
17 Pages

Chemokine Receptors CCR1 and CCR2 on Peripheral Blood Mononuclear Cells of Newly Diagnosed Patients with the CD38-Positive Chronic Lymphocytic Leukemia

  • Irina Kholodnyuk,
  • Alla Rivkina,
  • Laura Hippe,
  • Simons Svirskis,
  • Svetlana Kozireva,
  • Ildze Ventina,
  • Irina Spaka,
  • Marina Soloveichika,
  • Jelena Pavlova and
  • Sandra Lejniece
  • + 1 author

21 July 2020

Chemokines and their receptors direct migration and infiltration of immune cells. CCR1 and CCR2 maintain sequence similarity and respond to a number of the same chemokines secreted in lymphoid organs. Expression of CD38 on leukemic cells has been ass...

  • Review
  • Open Access
102 Citations
17,393 Views
14 Pages

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

  • Ilaria Saltarella,
  • Vanessa Desantis,
  • Assunta Melaccio,
  • Antonio Giovanni Solimando,
  • Aurelia Lamanuzzi,
  • Roberto Ria,
  • Clelia Tiziana Storlazzi,
  • Maria Addolorata Mariggiò,
  • Angelo Vacca and
  • Maria Antonia Frassanito

9 January 2020

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a p...

  • Review
  • Open Access
42 Citations
9,362 Views
12 Pages

13 December 2019

In the last decades CD38 has emerged as an attractive target for multiple myeloma (MM). CD38 is a novel multifunctional glycoprotein that acts as a receptor, adhesion molecule interacting with CD31 and as an ectoenzyme. As an ectoenzyme, CD38 functio...

  • Article
  • Open Access
1,929 Views
14 Pages

Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma

  • Rubén Osuna-Gómez,
  • Jordi López-Pardo,
  • Maria Mulet,
  • Josep Nomdedéu,
  • Elisabet Cantó,
  • Rosa Ortin,
  • Ángela Sánchez Cayuela,
  • Ma Àngels Ortiz,
  • Albert Guinart-Cuadra and
  • Silvia Vidal

30 September 2025

Background/Objectives: CD38-targeting monoclonal antibodies isatuximab and daratumumab have revolutionized multiple myeloma (MM) treatment, but a deeper understanding of their distinct mechanisms is crucial for therapeutic optimization. Methods: We u...

  • Review
  • Open Access
29 Citations
12,807 Views
21 Pages

Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance

  • Danilo De Novellis,
  • Raffaele Fontana,
  • Valentina Giudice,
  • Bianca Serio and
  • Carmine Selleri

30 December 2022

CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic plasma cells in multiple myeloma (MM), making them ideal therapeutic targets. Anti-CD38 monoclonal antibodies, such as approved daratumumab and isatuximab, are curren...

  • Feature Paper
  • Review
  • Open Access
4 Citations
4,742 Views
21 Pages

8 September 2022

CD38 was first discovered as a T-cell antigen and has since been found ubiquitously expressed in various hematopoietic cells, including plasma cells, NK cells, B cells, and granulocytes. More importantly, CD38 expression levels on malignant hematopoi...

  • Article
  • Open Access
65 Citations
9,163 Views
19 Pages

Assessing Molecular Docking Tools to Guide Targeted Drug Discovery of CD38 Inhibitors

  • Eric D. Boittier,
  • Yat Yin Tang,
  • McKenna E. Buckley,
  • Zachariah P. Schuurs,
  • Derek J. Richard and
  • Neha S. Gandhi

A promising protein target for computational drug development, the human cluster of differentiation 38 (CD38), plays a crucial role in many physiological and pathological processes, primarily through the upstream regulation of factors that control cy...

  • Article
  • Open Access
6 Citations
3,052 Views
15 Pages

Downregulation of miR-140-3p Contributes to Upregulation of CD38 Protein in Bronchial Smooth Muscle Cells

  • Yoshihiko Chiba,
  • Mayumi Matsumoto,
  • Motohiko Hanazaki and
  • Hiroyasu Sakai

27 October 2020

In allergic bronchial asthma, an increased smooth muscle contractility of the airways is one of the causes of the airway hyperresponsiveness (AHR). Increasing evidence also suggests a possible involvement of microRNAs (miRNAs) in airway diseases, inc...

  • Article
  • Open Access
32 Citations
6,065 Views
14 Pages

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma

  • Yung-Hsing Huang,
  • Mohammad Reza Vakili,
  • Ommoleila Molavi,
  • Yuen Morrissey,
  • Chengsheng Wu,
  • Igor Paiva,
  • Amir Hasan Soleimani,
  • Forugh Sanaee,
  • Afsaneh Lavasanifar and
  • Raymond Lai

20 February 2019

STAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited, partly related to some of their pharmacologic properties. T...

  • Article
  • Open Access
18 Citations
6,594 Views
15 Pages

Effects of Three Lipidated Oxytocin Analogs on Behavioral Deficits in CD38 Knockout Mice

  • Stanislav M. Cherepanov,
  • Shirin Akther,
  • Tomoko Nishimura,
  • Anna A. Shabalova,
  • Akira Mizuno,
  • Wataru Ichinose,
  • Satoshi Shuto,
  • Yasuhiko Yamamoto,
  • Shigeru Yokoyama and
  • Haruhiro Higashida

16 October 2017

Oxytocin (OT) is a nonapeptide that plays an important role in social behavior. Nasal administration of OT has been shown to improve trust in healthy humans and social interaction in autistic subjects. As is consistent with the nature of a peptide, O...

  • Article
  • Open Access
7 Citations
5,543 Views
20 Pages

Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma

  • Margaux Lejeune,
  • Elodie Duray,
  • Matthias Peipp,
  • Béatrice Clémenceau,
  • Frédéric Baron,
  • Yves Beguin and
  • Jo Caers

20 June 2021

Multiple myeloma (MM) is an incurable cancer characterized by the proliferation and accumulation of monoclonal plasma cells in the bone marrow. The monoclonal anti-CD38 daratumumab has taken a central place in the different treatment regimens for new...

  • Article
  • Open Access
32 Citations
11,570 Views
14 Pages

Design, Synthesis and SAR Studies of NAD Analogues as Potent Inhibitors towards CD38 NADase

  • Shengjun Wang,
  • Wenjie Zhu,
  • Xuan Wang,
  • Jianguo Li,
  • Kehui Zhang,
  • Liangren Zhang,
  • Yong-Juan Zhao,
  • Hon Cheung Lee and
  • Lihe Zhang

29 September 2014

Nicotinamide adenine dinucleotide (NAD), one of the most important coenzymes in the cells, is a substrate of the signaling enzyme CD38, by which NAD is converted to a second messenger, cyclic ADP-ribose, which releases calcium from intracellular calc...

  • Review
  • Open Access
68 Citations
9,232 Views
17 Pages

27 November 2019

CD38 is a multifunctional cell surface protein endowed with receptor/enzymatic functions. The protein is generally expressed at low/intermediate levels on hematological tissues and some solid tumors, scoring the highest levels on plasma cells (PC) an...

of 661